Happy to share that our case series on transthyretin cardiac amyloidosis (ATTR-CA) in a Safety-Net Hospital is now published in @JACCJournals, #JACCCaseReports🎉
Read the full article here: https://t.co/xSY7Hyw3DB
It is the International Day for Interventional Cardiology! Today we honor the 49th anniversary of Dr. Andreas Gruentzig's first #angioplasty & a breakthrough that changed 🫀 care forever.
#ACCPresident@DrRoxMehran reflects on the lasting impact of that innovation ⬇️
Among patients with atherosclerotic cardiovascular disease, targeting an LDL cholesterol level below 55 mg per deciliter led to a lower 3-year risk of cardiovascular events than targeting a level below 70 mg per deciliter. Full Ez-PAVE trial results and Research Summary: https://t.co/TVjqbASTxC
ICI #myocarditis can present late & atypically. Biventricular ICI-M w/ predominant RV failure 17 months after pembrolizumab, a reminder to maintain long-term vigilance for #cardiotoxicity beyond the early Tx period. https://t.co/rtzL58baJV
#JACCCardioOnc@datsunian@MichaelR21
Heart failure prevention in women requires attention to sex-specific risk factors often missed by conventional risk assessment.
Pregnancy complications, endometriosis, menopause, and cancer treatment can shape CV risk & need to be recognized accordingly.
https://t.co/erzEaKU6eJ
Mortality from cardiogenic shock is significantly affected by concomitant renal failure. See how renal vascular tone affects whether MCS can augment renal perfusion & the potential of pharmacologic therapies to optimize renal support. https://t.co/fPes4rNNVZ #JACCBTS
The global burden attributable to elevated LDL-C has grown substantially since 1990, according to findings from the Global Burden of Disease Study 2023 Cholesterol Collaborators.
Read more: https://t.co/ONSqpT46jc #cvLipids#cvPrev
Anomalous aortic origin of a #coronary artery (#AAOCA) can lead to ischemia and sudden cardiac death. Check out this #JACCIMG state-of-the-art review on standardized nomenclature describing anatomic and morphologic features of AAOCA. https://t.co/kNm86F4UUy @chrisgraeni
2025 was a landmark year for cardiogenic shock and mechanical circulatory support research.
✅ DanGer Shock trial
✅ 2025 ACC/AHA/Multisociety guideline in #JACC on #cvACS management
✅ 2025 ACC Expert Consensus Statement in JACC on cardiogenic shock
🔗: https://t.co/sXpEwOqcYa
After hospitalization for #heartfailure, most new prescriptions for guideline-directed medical therapy went unfilled, and most newly initiated prescriptions did not persist to the six-month mark.
Read the journal scan for more ➡️ https://t.co/TZWPwjQvxQ #CardioX
A 🆕 ACC Scientific Statement published in #JACC provides evidence-based guidance on the use of DOACs in primary and secondary prevention of thrombotic events.
Get full details ➡️ https://t.co/eJTQ6t4EPn #cvCoag#cvVTE#CardioX
Heart failure prevention cannot take a one-size-fits-all approach.
Female-specific factors, including pregnancy complications, early menopause, and endometriosis, can all influence future heart failure risk and should be part of CV risk assessment.
https://t.co/VK524qpZo3
Looking for guidance in cardiology?
Connect with mentors across #NewYork!
Students, residents, fellows, and early-career cardiologists — this program is for YOU!!!
One conversation can change a career..
One mentor can change a life...
Apply now!
https://t.co/KJ6GljZpd7
A successful day of learning and thoughtful discussion with leaders in heart failure and cardiogenic shock. Grateful for the opportunity to engage with experts shaping the future of cardiovascular care. @KadoshBernard@ElizabethAlliMD@NazeeraGhanie@HamzaTarigHamza
Engage ❤️ Educate ❤️ Empower ❤️
so our communities can embrace a ❤️ healthy living and thrive.
Thank you to all our @NYSCACC volunteers who participated in raising ❤️ health in Brooklyn @BKLYNlibrary@ACCinTouch